<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: In addition to its efficacy in reducing <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi>, <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> has been shown to significantly decrease plasma triacylglycerol </plain></SENT>
<SENT sid="1" pm="."><plain>The use of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> may be beneficial in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, who usually have increased triacylglycerol levels </plain></SENT>
<SENT sid="2" pm="."><plain>However, its effects on the metabolism of triacylglycerol-rich <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> in type 2 diabetic patients remains unknown </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We performed a randomised double-blind crossover trial of 6-week treatment with placebo or <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 20 mg in eight patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who were being treated with oral <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering agents </plain></SENT>
<SENT sid="4" pm="."><plain>In each patient, an in vivo kinetic study of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B (ApoB)-containing <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> with [<z:chebi fb="18" ids="36928">13C</z:chebi>]leucine was performed at the end of each treatment period </plain></SENT>
<SENT sid="5" pm="."><plain>A central randomisation centre used computer-generated tables to allocate treatments </plain></SENT>
<SENT sid="6" pm="."><plain>Participants, caregivers and those assessing the outcomes were blinded to group assignment </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:chebi fb="0" ids="38545">Rosuvastatin</z:chebi> 20 mg significantly reduced plasma <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi>, triacylglycerol and total ApoB </plain></SENT>
<SENT sid="8" pm="."><plain>It also significantly reduced ApoB pool sizes of larger triacylglycerol-rich <z:chebi fb="1" ids="39027">VLDL</z:chebi> particles (VLDL1; p = 0.011), smaller <z:chebi fb="1" ids="39027">VLDL</z:chebi> particles (VLDL2; p = 0.011), intermediate density <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> (IDL; p = 0.011) and <z:chebi fb="15" ids="39026">LDL</z:chebi> (p = 0.011) </plain></SENT>
<SENT sid="9" pm="."><plain>This reduction was associated with a significant increase in the total fractional catabolic rate of VLDL1-ApoB (6.70 +/- 3.24 vs 4.52 +/- 2.34 pool/day, p = 0.049), VLDL2-ApoB (8.72 +/- 3.37 vs 5.36 +/- 2.64, p = 0.011), IDL-ApoB (7.06 +/- 1.68 vs 4.21 +/- 1.51, p = 0.011) and <z:chebi fb="15" ids="39026">LDL</z:chebi>-ApoB (1.02 +/- 0.27 vs 0.59 +/- 0.13, p = 0.011) </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="38545">Rosuvastatin</z:chebi> did not change the production rates of VLDL2-, IDL- or <z:chebi fb="15" ids="39026">LDL</z:chebi>-, but did reduce VLDL1-ApoB production rate (12.4 +/- 4.5 vs 19.5 +/- 8.4 mg kg(-1) day(-1), p = 0.035) </plain></SENT>
<SENT sid="11" pm="."><plain>No side effects of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> were observed during the study </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS/INTERPRETATION: In type 2 diabetic patients <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 20 mg not only induces a significant increase of <z:chebi fb="15" ids="39026">LDL</z:chebi>-ApoB catabolism (73%), but also has favourable effects on the catabolism of triacylglycerol-rich <z:chebi fb="2" ids="6495">lipoproteins</z:chebi>, e.g. a significant increase in the catabolism of VLDL1-ApoB (48%), VLDL2-ApoB (63%) and IDL-ApoB (68%), and a reduction in the production rate of VLDL1-ApoB (-36%) </plain></SENT>
<SENT sid="13" pm="."><plain>The effects of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> on the metabolism of triacylglycerol-rich <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> may be beneficial for prevention of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in type 2 diabetic patients </plain></SENT>
</text></document>